CAS: 2377352-49-1; (R)-1'-(3-(3,4-Dihydro-1,5-Naphthyridin-1(2H)-yl)-1H-Pyrazolo[3,4-B]Pyrazin-6-yl)-3H-Spiro[benzofuran-2,4'-Piperidin]-3-Amine
- 英文名称(R)-1'-(3-(3,4-Dihydro-1,5-Naphthyridin-1(2H)-yl)-1H-Pyrazolo[3,4-B]Pyrazin-6-yl)-3H-Spiro[benzofuran-2,4'-Piperidin]-3-Amine
- 中文名称(R)-1'-(3-(3,4-二氢-1,5-萘啶-1(2H)-基)-1H-吡唑并[3,4-B]吡嗪-6-基)-3H-.[苯并呋喃-2,4'-哌啶]-3-胺
- IUPAC名称(R)-1'-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4'-piperidin]-3-amine
- 其它别名Spiro[benzofuran-2(3H),4'-Piperidin]-3-Amine, 1'-[3-(3,4-Dihydro-1,5-Naphthyridin-1(2H)-yl)-1H-Pyrazolo[3,4-B]Pyrazin-6-Yl]-, (3R)-; Migoprotafib; (R)-1'-(3-(3,4-Dihydro-1,5-Naphthyridin-1(2H)-yl)-1H-Pyrazolo[3,4-B]Pyrazin-6-yl)-3H-Spiro[benzofuran-2,4'-Piperidin]-3-Amine; (R)-1'-(3-(3,4-Dihydro-1,5-Naphthyridin-1(2H)-yl)-1H-Pyrazolo[3,4-B]Pyrazin-6-yl)-3H-Spiro[benzofuran-2,4'-Piperidin]-3-Amine
- CAS编号2377352-49-1
- FDA UNII编号:ABR1HZ0ZG8
- 分子式:C25H26N8O分子量:454.54
- 产品CID: 1180682
- 产品分类Inhibitors/Agonists → MAPK/ERK Pathway → p38 MAPK | Inhibitors/Agonists → MAPK/ERK Pathway → ERK
物理性质
- 沸点714.1±60.0 °C(预测)
- 密度1.48±0.1 g/cm3(预测)
- pKa:9.52±0.50(预测)
- LogP:2.4
- 外观形态淡黄色至黄色固体
- 储存条件Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
- 产品应用该化合物是SHP2 甲状腺抑制剂.GDC-171显示生物化学和细胞模型的超强能量,预测人体PK剖面图表明,它将在合理剂量下实现目标接触.GCD-1971显示,IC50低于检测测量极限(0.001微米),而IC50在与组织活跃的E76K SHP 2变异体的同一生物化学分析中转至0.17微米.
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2905122000-异丙醇
2905143000-叔丁醇
2922110001-单乙醇胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
Taylor AM, Williams BR, Giordanetto F, Kelley EH, Lescarbeau A, Shortsleeves K, Tang Y, Walters WP, Arrazate A, Bowman C, Brophy E, Chan EW, Deshmukh G, Greisman JB, Hunsaker TL, Kipp DR, Saenz Lopez-Larrocha P, Maddalo D, Martin IJ, Maragakis P, Merchant M, Murcko M, Nisonoff H, Nguyen V, Nguyen V, Orozco O, Owen C, Pierce L, Schmidt M, Shaw DE, Smith S, Therrien E, Tran JC, Watters J, Waters NJ, Wilbur J, Willmore L. Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors. J Med Chem. 2023 Sep 29. doi: 10.1021/acs.jmedchem.3c00483. Epub ahead of print.
📝 需求与反馈
尽可能描述清楚需求与问题信息
